At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 155 enrolled
Drug / intervention
prasugrel +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Pharmacokinetic and Pharmacodynamic Comparison of Prasugrel and Clopidogrel in Very Elderly Versus Non-Elderly Aspirin-Treated Subjects With Stable Coronary Artery Disease
In Brief
A Phase 1 clinical trial evaluating prasugrel and clopidogrel for Coronary Artery Disease. Completed, enrolled 155 participants across 7 sites in 4 countries.
Detailed Summary
The 5-milligram (mg) maintenance dose (MD) of prasugrel in very elderly patients with coronary artery disease produces a pharmacodynamic response within the same therapeutic range as 10-mg MD in non-elderly patients.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCoronary Artery Disease
CountriesIreland, Netherlands, Sweden, United States
CollaboratorsDaiichi Sankyo Co., Ltd.
Timeline
Phase 1CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartMar 2010
First PostedApr 2010
Primary CompletionOct 2011
TodayJul 2026
First PostedApr 21, 2010
Enrollment StartMar 1, 2010
Primary CompletionOct 1, 2011
TodayJul 2, 2026
Enrollment to primary: 1.6 yearsPosted 16.2 years ago
Interventions
prasugreldrug
administered orally, daily for 12 days
clopidogreldrug
Administered orally, daily for 12 days